Retain intermittent dosing of carbapenems.
作者信息
Hanberger H, Nilsson L E
出版信息
Antimicrob Agents Chemother. 1994 Jan;38(1):159-60. doi: 10.1128/AAC.38.1.159.
Abstract
摘要
相似文献
1
Retain intermittent dosing of carbapenems.
Antimicrob Agents Chemother. 1994 Jan;38(1):159-60. doi: 10.1128/AAC.38.1.159.
2
New developments in carbapenems.
Clin Microbiol Infect. 2008 Dec;14(12):1102-11. doi: 10.1111/j.1469-0691.2008.02101.x.
3
Lucasti et al in the May 2008 issue of Clinical Therapeutics.
Clin Ther. 2008 Oct;30(10):1934; author reply 1934-6. doi: 10.1016/s0149-2918(08)00343-3.
4
Doripenem (Doribax)--a new parenteral carbapenem.
Med Lett Drugs Ther. 2008 Jan 28;50(1278):5-7.
5
[Carbapenems in pediatric practice].
Antibiot Khimioter. 2001;46(12):8-16.
6
Doripenem: a new carbapenem.
S D Med. 2008 Jul;61(7):260-1.
7
Carbapenems: do they have a future?
J Med Microbiol. 2011 Sep;60(Pt 9):1229-1230. doi: 10.1099/jmm.0.031013-0. Epub 2011 Jun 30.
8
Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2003 and 2004.
Int J Antimicrob Agents. 2005 Nov;26(5):420-3. doi: 10.1016/j.ijantimicag.2005.08.002. Epub 2005 Oct 10.
9
[Pediatric use of carbapenems].
Arch Pediatr. 2010 Jun;17(6):760-1. doi: 10.1016/S0929-693X(10)70097-X.
10
Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Am Surg. 1991 Dec;57(12):769-74.
引用本文的文献
1
Comparative pharmacokinetics of the carbapenems: clinical implications.
Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002.
2
Continuous infusion of beta-lactam antibiotics.
Clin Pharmacokinet. 1998 Nov;35(5):391-402. doi: 10.2165/00003088-199835050-00004.
3
Meropenem clinical pharmacokinetics.
Clin Pharmacokinet. 1995 Apr;28(4):275-86. doi: 10.2165/00003088-199528040-00002.
本文引用的文献
1
Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting the antibiotic.
Hosp Pract (Off Ed). 1993 Jun;28 Suppl 1:16-20. doi: 10.1080/21548331.1993.11442930.
2
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
Antimicrob Agents Chemother. 1987 Sep;31(9):1420-2. doi: 10.1128/AAC.31.9.1420.
3
Role of pharmacokinetics in the outcome of infections.
Antimicrob Agents Chemother. 1988 Mar;32(3):289-97. doi: 10.1128/AAC.32.3.289.
4
Subpopulations of variants resistant to imipenem in Pseudomonas aeruginosa.
J Antimicrob Chemother. 1988 Nov;22(5):643-9. doi: 10.1093/jac/22.5.643.
5
Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms.
Rev Infect Dis. 1988 Jul-Aug;10(4):892-8. doi: 10.1093/clinids/10.4.892.
6
Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
Antimicrob Agents Chemother. 1990 Jul;34(7):1336-41. doi: 10.1128/AAC.34.7.1336.
7
Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model.
Antimicrob Agents Chemother. 1991 Sep;35(9):1905-10. doi: 10.1128/AAC.35.9.1905.
8
Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.
Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):927-34. doi: 10.1007/BF02005446.
9
Continuous infusion of beta-lactam antibiotics.
Antimicrob Agents Chemother. 1992 Dec;36(12):2577-83. doi: 10.1128/AAC.36.12.2577.
Zotero 插件